chevron_leftBack
As of 24 April 2025, Imagion Biosystems Ltd. has a market cap of $1.54M USD, ranking #38349 globally and #1543 in Australia. It ranks #3892 in the Healthcare sector, and #208 in the Diagnostics & Research industry.
Key Stats
Market Cap
$1.54MUSD
2.42M AUD
Enterprise Value
$1.66MUSD
2.59M AUD
Revenue (TTM)
$1.7MUSD
2.67M AUD
EBITDA (TTM)
-$447.04KUSD
-700.09K AUD
Net Income (TTM)
-$1.32MUSD
-2.07M AUD
EBITDA Margin
-26%
Profit Margin
-78%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Diagnostics & Research
Founded
2016
Website
imagionbiosystems.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 17% | 0% | -28% | -32% | -75% | -82% |
Upcoming Earnings
Earnings Date
Fri, May 30
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
IBX
Imagion Biosystems Ltd
ISIN: AU000000IBX6
Shares Out.:
Shares Outstanding:
201.341M1
Shares Float:
201.152M2
|
0.0140 AUD | |
|
IBXXF
Imagion Biosystems Ltd
ISIN: AU000000IBX6
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.0100 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Imagion Biosystems Ltd.
Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to detect cancer. The company has collaboration with Siemens MRI to support the Phase 2 study of MagSense HER2 imaging agent. Imagion Biosystems Limited was incorporated in 2016 and is based in South Melbourne, Australia.
